🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesA1C target achievement rates — sema vs tirz comparison Page 2

A1C target achievement rates — sema vs tirz comparison

TrialTracker_MD Thu, Mar 12, 2026 at 9:22 PM 8 replies 266 viewsPage 2 of 2
CryptoCarl
Member
789
3,456
May 2024
Arizona
Mar 13, 2026 at 12:12 AM#6

Does anyone know if insurance continues to cover semaglutide once the diabetes diagnosis is removed? That's my concern — I'm in a similar trajectory and worried about losing coverage.

26 19CryptoCarl, MariaRD, AussieAnna and 23 others
Reply Quote Save Share Report
TrialTracker_MD
Senior Member
2,345
15,678
Jan 2024
Maryland
Mar 13, 2026 at 12:29 AM#7
Does anyone know if insurance continues to cover semaglutide once the diabetes diagnosis is removed?

This varies hugely by plan. Some will switch the indication to obesity management (BMI-based), some require a new prior auth, and some will drop coverage entirely. It's worth having a proactive conversation with your endo about coding strategy before the diagnosis is officially changed. Some docs will keep "insulin resistance" or "pre-diabetes" as a code even after A1C normalizes, which can preserve coverage.

Last edited: Mar 13, 2026 at 5:29 AM
33 7stefan_berlin, Dr.EM_Chicago, pete_RVA and 30 others
Reply Quote Save Share Report
Dr.EndoEP
Member
267
1,234
Oct 2024
El Paso, TX
Mar 13, 2026 at 12:46 AM#8

Good point about insurance. My endo is keeping me coded as "obesity, BMI 31.5" which is still accurate and is a covered indication on my plan. She was very thoughtful about the timing. The T2D history code is also documented which helps with prior auths.

27 21FranDenver, Dr.BariatricHTX, LindaRN_retired and 24 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
SleepDoc_PDX
Member
289
1,234
Sep 2024
Portland, OR
Mar 13, 2026 at 1:03 AM#9

For those who like numbers, here's what the research says about this kind of trajectory:

The STEP 2 trial showed an average A1C reduction of 1.6 percentage points on semaglutide 2.4mg in patients with T2D. An A1C drop of 3.8 points (9.2 to 5.4) is well above average, which suggests diet/exercise modifications played a significant complementary role. The weight loss of 66 lbs (~25%) is also above the trial average of ~10%, further supporting that lifestyle changes amplified the pharmacological effect.

Great result. The data backs up the approach.

2 6sophie_paris, mel_PDX
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
GLP-1 and beta-cell preservation — regeneration evidence15 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register